Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alastin Regenerating Skin Nectar is a specialized topical formulation designed to enhance the skin's natural healing and rejuvenation processes, particularly in conjunction with aesthetic procedures. Developed by Alastin Skincare and now part of the Galderma portfolio, the product centers on proprietary TriHex Technology, a blend of active peptides and botanicals. This technology is engineered to clear out damaged collagen and elastin fibers within the extracellular matrix (ECM)—a process often referred to as recycling the ECM—while simultaneously stimulating the synthesis of new, healthy structural proteins. By optimizing the skin's environment prior to and following procedures such as laser resurfacing, chemical peels, and microneedling, the Nectar aims to improve clinical outcomes, reduce recovery time, and minimize post-procedure symptoms like redness and swelling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alastin Regenerating Skin Nectar.